Individualized optimization of colistin loading doses
Tóm tắt
Colistin remains one of the few available options for the treatment of infections caused by resistant bacteria. Pharmacokinetic (PK) studies have been successful in estimating the appropriate colistin methanesulfonate (CMS) dose to achieve a target colistin concentration. Currently, there is a consensus that the dose of CMS should vary according to the patient renal function since CMS is mainly eliminated by renal route. For this same reason, the loading dose should vary according to the patient's renal capacity; however, this is not the current clinical practice. In this study we develop a framework to determine two key parameters for the loading dose regimen: (1) the optimal dose according to the characteristics (renal function and weight) of the patient; (2) the waiting time before the maintenance dose. Based on a previous PK model, our framework allows a fast parameter sweep so as to select optimal loading dose and waiting time minimizing the deviation between the plasma concentration and a target value. The results showed that patients presenting low creatinine clearance (CrCL) should receive a lower CMS loading dose with longer interval to start maintenance treatment to avoid nephrotoxic colistin concentrations. In cases of high CrCL, the dose should be higher and the interval to the next dose shorter to avoid subtherapeutic concentrations. Optimization of the loading dose should considerably improve colistin therapy, as the target concentration is reached more quickly, without reaching toxic values.
Tài liệu tham khảo
Davies DS (2021) BSAC Vanguard series: are we finally finding our voice on antimicrobial resistance? J Antimicrob Chemother 77(2):281–282. https://doi.org/10.1093/jac/dkab411
Hofer U (2019) The cost of antimicrobial resistance. Nat Rev Microbiol 17(1):3–3
Organization WH (2021) Global antimicrobial resistance and use surveillance system (GLASS) Report: 2021
De Oliveira DM, Forde BM, Kidd TJ, Harris PN, Schembri MA, Beatson SA, Paterson DL, Walker MJ (2020) Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev 33(3):e00181-e119
Gontijo AVL, Pereira SL, de Lacerda BH (2021) Can drug repurposing be effective against carbapenem-resistant Acinetobacter baumannii? Curr Microbiol 79(1):13. https://doi.org/10.1007/s00284-021-02693-5
Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L (2018) Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 18(4):391–400. https://doi.org/10.1016/S1473-3099(18)30099-9
Liang CA, Lin YC, Lu PL, Chen HC, Chang HL, Sheu CC (2018) Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect 24(8):908.e901-908.e907. https://doi.org/10.1016/j.cmi.2017.10.033
Schuertz KF, Tuon FF, Palmeiro JK, Conte D, Telles JPM, Trevisoli LE, Dalla-Costa LM (2018) Bacteremia and meningitis caused by OXA-23-producing Acinetobacter baumannii–molecular characterization and susceptibility testing for alternative antibiotics. Braz J Microbiol 49:199–204
Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, Dishon Benattar Y, Bitterman R, Neuberger A, Carmeli Y, Paul M (2018) Treatment outcomes of colistin- and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial. Clin Infect Dis 69(5):769–776. https://doi.org/10.1093/cid/ciy988
Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A III, Forrest A, Bulitta JB, Tsuji BT (2010) Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30(12):1279–1291. https://doi.org/10.1592/phco.30.12.1279
Garonzik S, Li J, Thamlikitkul V, Paterson D, Shoham S, Jacob J, Silveira F, Forrest A, Nation R (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55(7):3284–3294
Nation RL, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Forrest A, Paterson DL, Li J, Silveira FP (2017) Dosing guidance for intravenous colistin in critically ill patients. Clin Infect Dis 64(5):565–571
Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I (2019) International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti‐infective Pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacotherapy 39(1):10–39
Sorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Álvarez-Lerma F, Knobel H, Benito N, Horcajada JP (2013) Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 13(1):1–9
Gontijo AVL, Cavalieri AVG (2021) Optimal control for colistin dosage selection. J Pharmacokinet Pharmacodyn 48(6):803–813. https://doi.org/10.1007/s10928-021-09769-6
Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U (2015) Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15(2):225–234
Boyce WE, DiPrima RC, Meade DB (2021) Elementary differential equations and boundary value problems. Wiley, New York
Bauer LA (2008) Applied clinical pharmacokinetics, 2nd edn. McGraw-Hill Medical, New York
Karaiskos I, Friberg LE, Pontikis K, Ioannidis K, Tsagkari V, Galani L, Kostakou E, Baziaka F, Paskalis C, Koutsoukou A, Giamarellou H (2015) Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically Ill patients. Antimicrob Agents Chemother 59(12):7240–7248. https://doi.org/10.1128/AAC.00554-15
Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE (2012) Application of a loading dose of colistin methanesulfonate in critically Ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56(8):4241–4249. https://doi.org/10.1128/AAC.06426-11
Bellos I, Pergialiotis V, Frountzas M, Kontzoglou K, Daskalakis G, Perrea DN (2020) Efficacy and safety of colistin loading dose: a meta-analysis. J Antimicrob Chemother 75(7):1689–1698
Vardakas KZ, Rellos K, Triarides NA, Falagas ME (2016) Colistin loading dose: evaluation of the published pharmacokinetic and clinical data. Int J Antimicrob Agents 48(5):475–484
Grégoire N, Aranzana-Climent V, Magréault S, Marchand S, Couet W (2017) Clinical pharmacokinetics and pharmacodynamics of colistin. Clin Pharmacokinet 56(12):1441–1460
Karaiskos I, Souli M, Galani I, Giamarellou H (2017) Colistin: still a lifesaver for the 21st century? Expert Opin Drug Metab Toxicol 13(1):59–71
Aggarwal R, Dewan A (2018) Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study. Ann Clin Microbiol Antimicrob 17(1):1–8
Dai C, Xiao X, Li J, Ciccotosto GD, Cappai R, Tang S, Schneider-Futschik EK, Hoyer D, Velkov T, Shen J (2019) Molecular mechanisms of neurotoxicity induced by polymyxins and chemoprevention. ACS Chem Neurosci 10(1):120–131. https://doi.org/10.1021/acschemneuro.8b00300
Eljaaly K, Bidell MR, Gandhi RG, Alshehri S, Enani MA, Al-Jedai A, Lee TC (2021) Colistin nephrotoxicity: meta-analysis of randomized controlled trials. Open Forum Infect Dis. https://doi.org/10.1093/ofid/ofab026
Ordooei Javan A, Shokouhi S, Sahraei Z (2015) A review on colistin nephrotoxicity. Eur J Clin Pharmacol 71(7):801–810
Cheah S-E, Wang J, Nguyen VTT, Turnidge JD, Li J, Nation RL (2015) New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 70(12):3291–3297
Albur M, Noel A, Bowker K, MacGowan A (2013) Colistin susceptibility testing: time for a review. J Antimicrob Chemother 69(5):1432–1434. https://doi.org/10.1093/jac/dkt503
Sorlí L, Luque S, Li J, Campillo N, Danés M, Montero M, Segura C, Grau S, Horcajada JP (2019) Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: dose is critical. J Infect 79(3):253–261
Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G (2009) Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 48(12):1724–1728. https://doi.org/10.1086/599225
Kristoffersson AN, Rognås V, Brill MJE, Dishon-Benattar Y, Durante-Mangoni E, Daitch V, Skiada A, Lellouche J, Nutman A, Kotsaki A, Andini R, Eliakim-Raz N, Bitterman R, Antoniadou A, Karlsson MO, Theuretzbacher U, Leibovici L, Daikos GL, Mouton JW, Carmeli Y, Paul M, Friberg LE (2020) Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria. Clin Microbiol Infect 26(12):1644–1650. https://doi.org/10.1016/j.cmi.2020.03.016
Katip W, Uitrakul S, Oberdorfer P (2017) Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients. Infect Drug Resist 10:293
Nazer LH, Anabtawi N (2017) Optimizing colistin dosing: is a loading dose necessary? Am J Health Syst Pharm 74(1):e9–e16. https://doi.org/10.2146/ajhp150876